2022
DOI: 10.1002/14651858.cd002795.pub3
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacotherapy for post traumatic stress disorder (PTSD)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
35
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 41 publications
(63 citation statements)
references
References 237 publications
0
35
0
1
Order By: Relevance
“…Serotonin deficiency is associated with the development of PTSD symptoms, such as impulsivity, hostility, aggression, depression and suicidal thoughts [ 38 ]. Other findings of altered 5-HT neurotransmission in PTSD include decreased serum 5-HT concentrations, decreased density of 5-HT reuptake sites in platelets and an altered response to CNS serotonergic provocation [ 39 , 40 ]. To sum up, altered 5-HT transmission may contribute to the development of PTSD symptoms, such as hypervigilance, increased surprise, impulsivity and intrusive memories.…”
Section: Introductionmentioning
confidence: 99%
“…Serotonin deficiency is associated with the development of PTSD symptoms, such as impulsivity, hostility, aggression, depression and suicidal thoughts [ 38 ]. Other findings of altered 5-HT neurotransmission in PTSD include decreased serum 5-HT concentrations, decreased density of 5-HT reuptake sites in platelets and an altered response to CNS serotonergic provocation [ 39 , 40 ]. To sum up, altered 5-HT transmission may contribute to the development of PTSD symptoms, such as hypervigilance, increased surprise, impulsivity and intrusive memories.…”
Section: Introductionmentioning
confidence: 99%
“…However, despite the aforementioned clinical strategies and the interventions proposed, clear guidelines for the management of these side effects are still lacking [ 9 ]. Moreover, the large number of people taking ADs worldwide, the use of ADs for several psychiatric disorders [ 11 , 12 , 13 , 14 , 15 ], and the potential adverse impact on treatment compliance and long-term outcome calls for broadening the range of approaches to AISD treatment.…”
Section: Introductionmentioning
confidence: 99%
“…In contemporary guidelines for the pharmacological management of anxiety and related disorders, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the recommended first-line treatments [19,20]. Though these groups of drugs are superior to placebos, their effectiveness is often modest [21][22][23], and only about 40-60% of patients show a clinically significant response to them in short-to medium-term clinical trials [24][25][26]. Moreover, around 16% of patients who are successfully treated with SSRIs or SNRIs develop a relapse of anxiety and obsessive-compulsive or posttraumatic stress symptoms when the drug is discontinued after a year of treatment [27], and treatment-emergent adverse effects often lead to non-adherence, particularly at higher doses of medication [28].…”
Section: Introductionmentioning
confidence: 99%